Measuring T cell response can add information about antivirus immunity provided by antibody test results. The study evaluates the impact of a third mRNA COVID-19 vaccine dose on T cell response and antibody production in kidney transplant recipients (25 KTRs) versus healthy controls (26 Hc). Results show a significant rise in S-activated CD4+CD154+IFN?+TNF?+ double producer cells in both KTRs (p=0.025) and Hc (p=0.009) as well as increased spike antibody response in KTRs (p=0.00019) and Hc (p=3.10-8) third-month post-third dose. Moreover, the study revealed a drop in seronegative KTRs (non-responders) from 9/25 (36%) pre-third dose to 2/25 (7%) at 3 months post-third dose while 5/9 (56%) of non-responders post-second dose showed specific T cell responses. Notably, the third dose significantly improved seroconversion rates in both KTRs and Hc, although Hc individuals exhibited higher antibody levels. Key words: mRNA COVID-19 vaccine, T cells, SARS-CoV-2 antibodies, Kidney transplantation, mRNA vaccination.

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Grupper A, Rabinowich L, Ben-Yehoyada M, Katchman E, Baruch R, Freund T, Hagin D, Shlomo SB, Schwartz D, Schwartz IF, Shashar M, Bassat OK, Halperin T, Turner D, Saiag E, Goykhman Y, Shibolet O, Levy S, Houri I, Katchman H. Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients. Transplant Proc. 2022;54:1439–1445. doi: 10.1016/j.transproceed.2022.02.011. PubMed DOI PMC

Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MIC, Wang L-F, Ooi EE, Kalimuddin S, Tambyah PA, Low JG-H, Tan Y-J, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z. PubMed DOI

Pross V, Sattler A, Lukassen S, Toth L, Thole LML, Siegle J, Stahl C, He A, Damm G, Seehofer D, Gotz C, Bayerl C, Jager P, Macke A, Eggeling S, Kirzinger B, Mayr T, Herbst H, Beyer K, Laue D, Kronke J, Braune J, Rosseck F, Kittner B, Friedersdorff F, Hubatsch M, Weinberger S, Lachmann N, Hofmann VM, Schrezenmeier E, Ludwig C, Schrezenmeier H, Jechow K, Conrad C, Kotsch K. SARS-CoV-2 mRNA vaccination-induced immunological memory in human nonlymphoid and lymphoid tissues. J Clin Invest. 2023:133. doi: 10.1172/JCI171797. PubMed DOI PMC

Taheri S. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. Int Urol Nephrol. 2023;55:791–802. doi: 10.1007/s11255-023-03471-x. PubMed DOI PMC

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20:1390–1400. doi: 10.1016/S1473-3099(20)30634-4. PubMed DOI PMC

Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA, Pallavicini L, Chinali A, Campisi D, Percivalle E, DiNapoli AP, Perno CF, Baldanti F. Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J Clin Microbiol. 2020:58. doi: 10.1128/JCM.01224-20. PubMed DOI PMC

Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. 2021;325:1784–1786. https://doi.org/10.1001/jama.2021.7489, https://doi.org/10.1001/jama.2021.4385. PubMed DOI PMC

Magicova M, Zahradka I, Fialova M, Neskudla T, Gurka J, Modos I, Hojny M, Raska P, Smejkal P, Striz I, Viklicky O. Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation. 2022;106:842–852. doi: 10.1097/TP.0000000000004044. PubMed DOI PMC

Trakarnvanich T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, Phochanasomboon K, Manomaipiboon A. Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant. Vaccine. 2022;40:6499–6511. doi: 10.1016/j.vaccine.2022.09.067. PubMed DOI PMC

Westhoff TH, Seibert FS, Anft M, Blazquez-Navarro A, Skrzypczyk S, Zgoura P, Meister TL, Pfaender S, Stumpf J, Hugo C, Viebahn R, Roch T, Stervbo U, Babel N. A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse. Kidney Int. 2021;100:1135–1136. doi: 10.1016/j.kint.2021.09.001. PubMed DOI PMC

Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X, Huang T, Zhong J, Wang Y, Wang X, Huang L, Xu L, Wang C, Chen L, Xiao X, Peng Y, Knight JC, Dong T, Cao B, Wang J. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022;3:e348–e356. doi: 10.1016/S2666-5247(22)00036-2. PubMed DOI PMC

Anft M, Blazquez-Navarro A, Paniskaki K, Skrzypczyk S, Appel H, Pfab T, Uhle A, Frahnert M, Barenbrock M, Bussemaker E, Horstrup J, Doevelaar A, Seibert FS, Holzer B, Stervbo U, Dolff S, Witzke O, Babel N, Westhoff TH. SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population. Kidney Int. 2021;99:1489–1490. doi: 10.1016/j.kint.2021.03.032. PubMed DOI PMC

Zhang R, Shin BH, Gadsden TM, Petrosyan A, Vo A, Ammerman N, Sethi S, Huang E, Peng A, Najjar R, Atienza J, Kim I, Jordan SC. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Transpl Infect Dis. 2022;24:e13813. doi: 10.1111/tid.13813. PubMed DOI PMC

Korth J, Jahn M, Dorsch O, Anastasiou OE, Sorge-Hadicke B, Eisenberger U, Gackler A, Dittmer U, Witzke O, Wilde B, Dolff S, Kribben A. Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech) Viruses. 2021:13. doi: 10.3390/v13050756. PubMed DOI PMC

Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662. doi: 10.1056/NEJMc2108861. PubMed DOI PMC

Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S, Caillard S. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326:1063–1065. doi: 10.1001/jama.2021.12339. PubMed DOI PMC

Vaiciuniene R, Sitkauskiene B, Bumblyte IA, Dalinkeviciene E, Ziginskiene E, Bagdonas D, Augliene R, Petruliene K, Bagdziuniene I, Skarupskiene I, Stankuviene A, Sauseriene J, Macinskas S, Valius L. Immune response after SARS-CoV-2 vaccination in kidney transplant patients. Medicina (Kaunas) 2021:57. doi: 10.3390/medicina57121327. PubMed DOI PMC

Bulnes-Ramos Á, Pozo-Balado MM, Olivas-Martínez I, Garrido-Rodríguez V, Bernal-Blanco G, Suárez-Benjumea A, Álvarez-Ríos AI, Lozano C, González-Corvillo C, Suñer-Poblet M, González-Roncero FM, Sánchez B, Maldonado-Calzado I, Lara-Ruiz JM, Gonzalez-Escribano MF, Pacheco YM. Factors associated with the humoral response after three doses of COVID-19 vaccination in kidney transplant recipients. Front Immunol. 2023;14:1099079. doi: 10.3389/fimmu.2023.1099079. PubMed DOI PMC

Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, Hoelzer B, Justine Konik M, Meister TL, Pfaender S, Steinmann E, Moritz Berger M, Brenner T, Kolsch U, Dolff S, Roch T, Witzke O, Schenker P, Viebahn R, Stervbo U, Westhoff TH, Babel N. The Magnitude and Functionality of SARS-CoV-2 reactive cellular and humoral immunity in transplant population is similar to the general population despite immunosuppression. Transplantation. 2021;105:2156–2164. doi: 10.1097/TP.0000000000003755. PubMed DOI PMC

Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, Budde K, Storz E, Pross V, Bergmann Y, Thole LM, Tizian C, Holsken O, Diefenbach A, Schrezenmeier H, Jahrsdorfer B, Zemojtel T, Jechow K, Conrad C, Lukassen S, Stauch D, Lachmann N, Choi M, Halleck F, Kotsch K. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021:131. doi: 10.1172/JCI150175. PubMed DOI PMC

Kelly NEW, De Barra C, Shaamile F, Holland A, Shaw L, Mallon PWG, O’Connell J, Hogan AE, O’Shea D. Antigen specific T cells in people with obesity at five months following ChAdOx1 COVID-19 vaccination. Int J Obes (Lond) 2023;47:83–86. doi: 10.1038/s41366-022-01235-8. PubMed DOI PMC

Zhao S, Mok CKP, Tang YS, Chen C, Sun Y, Chong KC, Hui DSC. Inferring Incidence of Unreported SARS-CoV-2 Infections Using Seroprevalence of Open Reading Frame 8 Antigen, Hong Kong. Emerg Infect Dis. 2024;30:325–328. doi: 10.3201/eid3002.231332. PubMed DOI PMC

Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi: 10.1136/bmj-2021-068632. PubMed DOI PMC